Early prediction and prevention of pre-eclampsia

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 25, Issue 3, 2011, Pages 343-354

  Leslie, Karin ^a   Thilaganathan, Basky ^a   Papageorghiou, Aris ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

biomarkers; mean arterial pressure; pre eclampsia; screening; uterine artery Doppler

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; BIOLOGICAL MARKER; CALCIUM; CYSTATIN C; ENDOGLIN; HEPARIN; IMMUNOGLOBULIN; ISCHEMIA MODIFIED ALBUMEN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PENTRAXIN 3; PLACENTAL GROWTH FACTOR; PLASMA PROTEIN 13; PREGNANCY ASSOCIATED PLASMA PROTEIN A; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

DISEASE MARKER; DISEASE PREDISPOSITION; DOPPLER FLOWMETRY; DRUG EFFICACY; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPOXIA; KIDNEY DYSFUNCTION; MATERNAL DISEASE; MEAN ARTERIAL PRESSURE; NONHUMAN; PATHOGENESIS; PATIENT COUNSELING; PLACENTA FUNCTION; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SCREENING TEST; UTERINE ARTERY DOPPLER;

BIOLOGICAL MARKERS; BLOOD PRESSURE; EARLY DIAGNOSIS; FEMALE; HUMANS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; ULTRASONOGRAPHY, DOPPLER;

EID: 79955837910     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2011.01.002     Document Type: Review

References (69)

1. Antenatal care: routine care for the healthy pregnant woman CG62. National Collaborating Centre for Women's and Children's Health; www.nice.org.uk.
2. Yu CK, Smith GC, Papageorghiou AT et al. Fetal medicine foundation second trimester screening Group. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol 2005; 193: 429-436. (Pubitemid 41159538)
3. Khan KS,Wojdyla D, Say L et al.WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367: 1066-1074.
4. Papageorghiou AT. Predicting and preventing pre-eclampsia-where to next? Ultrasound Obstet Gynecol 2008; 31: 367-370.
5. Conde-Agudelo A, Villar J & Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004; 104: 1367-1391. (Pubitemid 40458737)
6. Campbell S, Diaz-Recasens J, Griffin DR, et al.Newdoppler technique for assessing uteroplacental blood flow1983; 1: 675-677.
7. Prefumo F, Sebire NJ & Thilaganathan B. Decreased endovascular trophoblast invasion in first trimester pregnancies with high-resistance uterine artery Doppler indices. Hum Reprod 2004; 19: 206-209. (Pubitemid 38072033)
8. Plasencia W, Maiz N, Bonino S et al. Uterine artery Doppler at 11 ? 0 to 13 ? 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007; 30: 742-749. (Pubitemid 47612696)
9. Papageorghiou AT, Yu CK, Bindra R et al. Fetal medicine foundation second trimester screening G. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001; 18: 441-449.
10. Melchiorre K, Wormald B, Leslie K et al. First-trimester uterine artery Doppler indices in term and preterm pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32: 133-137.
11. Whitley GS, Dash PR, Ayling LJ et al. Increased apoptosis in first trimester extravillous trophoblasts from pregnancies at higher risk of developing preeclampsia. Am J Pathol 2007; 170: 1903-1909. (Pubitemid 47339264)
12. Shennan A & Halligan A. Measuring blood pressure in normal and hypertensive pregnancy. Baillieres Clin Obstet Gynaecol 1999; 13: 1-26. (Pubitemid 29520819)
13. Cnossen JS, Vollebregt KC, de Vrieze N et al. Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia: systematic review and meta-analysis. BMJ 2008; 336: 1117-1120. (Pubitemid 351731742)
14. Magee L, Helewa M & Moutquin J. SOGC guidelines; diagnosis, evaluation and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008; 30(suppl): 1-48.
15. National Heart Foundation Australia Measuring blood pressure; information for professionals. Available at: www. heartfoundation.org.au.
16. Poon LC, Kametas NA, Pandeva I et al. Mean arterial pressure at 11(+0) to 13(+6) weeks in the prediction of preeclampsia. Hypertension 2008; 51: 1027-1033.
17. Zhong Y, Tuuli M & Odibo AO. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenat Diagn 2010; 30: 293-308.
18. Spencer K, Yu CK, Cowans NJ et al. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn 2005; 25: 949-953. (Pubitemid 41494994)
19. Spencer K, Cowans NJ, Chefetz I et al. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol 2007; 29: 128-134.
20. Khalil A, Cowans NJ, Spencer K et al. First trimester maternal serum placental protein 13 for the prediction of preeclampsia in women with a priori high risk. Prenat Diagn 2009; 29: 781-789.
21. Bale L & Conover C. Disruption of insulin like growth factor II imprinting during embryonic development rescues the dwarf phenotype of mice null for PAPP-A. J Endocrinol 2005; 186: 325-331. (Pubitemid 41167401)
22. Smith GC, Stenhouse EJ, Crossley JA et al. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 2002; 87: 1762-1767. (Pubitemid 34615266)
23. Spencer K, Cowans NJ & Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of preeclampsia. Prenat Diagn 2008; 28: 7-10. (Pubitemid 351251982)
24. Poon LC, Kametas NA, Maiz N et al. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 12-18.
25. Nicolaides KH, Bindra R, Turan OM et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006; 27: 13-17. (Pubitemid 43129084)
26. Akolekar R, Syngelaki A, Beta J et al. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenat Diag 2009; 29: 1103-1108.
27. Tjwa M, Luttun A, Autiero M et al. VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. Cell Tissue Res 2003; 314: 5.
28. Autiero M, Luttun A, Tjwa M et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003; 1: 1356-1370.
29. Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. New Engl J Med 2006; 355: 992-1005. erratum: N Engl J Med 2006; 355: 1840.
30. Rana S, Karumanchi SA, Levine RJ et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50: 137-142. (Pubitemid 46986022)
31. Akolekar R, Zaragoza E, Poon LC et al. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32: 732-739. erratum: Ultrasound Obstet Gynecol 2009; 33: 249.
32. Thadhani R, Mutter WP, Wolf M et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770-775. (Pubitemid 38269892)
33. Levine RJ,Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia.NEngl J Med 2004; 350: 672-683.
34. Powers RW, Roberts JM, Cooper KM et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005; 193: 185-191. (Pubitemid 40991843)
35. Smith GC, Crossley JA, Aitken DA et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 2007; 109: 1316-1324. (Pubitemid 46869870)
36. Baumann MU, Bersinger NA, Mohaupt MG et al. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008; 199: 266.e1-266.e6.
37. Prefumo F, Gaze DC, Papageorghiou AT et al. First trimester maternal serum ischaemia-modified albumin: a marker of hypoxia-ischaemia-driven early trophoblast development. Hum Reprod 2007; 22: 2029-2032. (Pubitemid 47062775)
38. D'Anna R, Baviera G, Giordano D et al. Second trimester neutrophil gelatinase-associated lipocalin as a potential prediagnostic marker of preeclampsia. Acta Obstetricia Gynecol Scand 2008; 87: 1370-1373.
39. D'Anna R, Baviera G, Giordano D et al. Neutrophil gelatinase-associated lipocalin serum evaluation through normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand 2010; 89: 275-278.
40. D'Anna R, Baviera G, Giordano D et al. First trimester serum PAPP-A and NGAL in the prediction of late-onset preeclampsia. Prenat Diagn 2009; 29: 1066-1068.
41. Banzola I, Farina A, Concu M et al. Performance of a panel of maternal serum markers in predicting preeclampsia at 11-15 weeks' gestation. Prenat Diagn 2007; 27: 1005-1010. (Pubitemid 350114297)
42. Strevens H, Wide-Swensson D, Torffvit O et al. Serum cystatin C for assessment of glomerular filtration rate in pregnant and non-pregnant women. Indications of altered filtration process in pregnancy. Scand J Clin Lab Investig 2002; 62: 141-147. (Pubitemid 34407551)
43. Franceschini N, Qiu C, Barrow DA et al. Cystatin C and preeclampsia: a case control study. Ren Fail 2008; 30: 89-95.
44. Kristensen K, Larsson I & Hansson SR. Increased cystatin C expression in the pre-eclamptic placenta. Mol Hum Reprod 2007; 13: 189-195.
45. Thilaganathan B, Ralph E, Papageorghiou AT et al. Raised maternal serum cystatin C: an early pregnancy marker for preeclampsia. Reprod Sci 2009; 16: 788-793.
46. Thilaganathan B, Wormald B, Zanardini C et al. Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. Obstet Gynecol 2010; 115: 1233-1238.
47. Levine RJ & Lindheimer MD. First-trimester prediction of early preeclampsia: a possibility at last!. Hypertension 2009; 53: 747-748.
48. Cetin I, Cozzi V, Papageorghiou AT et al. First trimester PTX3 levels in women who subsequently develop preeclampsia and fetal growth restriction. Acta Obstet Gynecol Scand 2009; 88: 846-849.
49. Kusanovic JP, Romero R, Chaiworapongsa T et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009; 22: 1021-1038.
50. Howarth C, Gazis A & James D. Asoociations of Type 1 diabetes mellitus, maternal vascular disease and complications of pregnancy. Diabet Med 2007; 24: 1229-1234. (Pubitemid 47621803)
51. Bhattacharya S, Campbell D & ListonW. Effect of body mass index on pregnancy outcomes in nulliparous womendelivering singleton babies. BMC Public Health 2007; 7: 168.
52. Villamor E & Cnattingius S. Interpregnancy weight change and risk of adverse pregnancy outcomes: a population based study. Lancet 2006; 368: 1164-1170. (Pubitemid 44441577)
53. Redman C, Sacks G & Sargent I. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180: 499-506. (Pubitemid 29093892)
54. Askie LM, Duley L, Henderson-Smart DJ et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 1791-1798. (Pubitemid 46782996)
55. Duley L, Henderson-Smart DJ, Meher S et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007 Apr 18; (2). CD004659.
56. Berkane N, Hertig A, Rondeau E et al. Hypertensive disorders of pregnancy; future perspectives. A French point of view. Curr Opin Obstet Gynecol 2008; 20: 107-109. (Pubitemid 351498759)
57. Trumbo P & Ellwood K. Supplemental calcium and risk reduction of hypertension, pregnancy induced hypertension and preeclampsia: an evidence based review by the US food and drug administration. Nutr Rev 2007; 65: 78-87. (Pubitemid 351804382)
58. Hofmeyr G, Duley L & Atallah A. Dietary calcium supplementation for prevention of pre-eclampsia and related problems: a systematic review and commentary. BJOG 2007; 114: 933-943. (Pubitemid 47052743)
59. Levine RJ, Hauth JC, Curet LB et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997; 337: 69-76. (Pubitemid 27284391)
60. Villar J, Abdel-Aleem H, Merialdi M et al. World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol 2006; 194: 639-649. (Pubitemid 43336425)
61. Steegers E, Dadelszen P, Duvekot J et al. Preeclampsia. Lancet 2010; 376: 631-644.
62. Chappell L, Seed P & Briley A. Effect of antioxidants on the occurrence of preeclampsia in women at increased risk; a randomised trial. Lancet 1999; 354: 810-816. (Pubitemid 29415585)
63. McCance DR, Holmes VA, Maresh MJ et al. Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial. Lancet 2010; 376: 259-266.
64. Poston L, Briley AL, Seed PT et al. Vitamins in Pre-eclampsia Trial C. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006; 367: 1145-1154.
65. Roberts JM, Myatt L, Spong CY et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 2010; 362: 1282-1291.
66. Rumbold AR, Crowther CA, Haslam RR et al. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 2006; 354: 1796-1806.
67. Ganapathy R, Whitley GS, Cartwright JE et al. Effect of heparin and fractionated heparin on trophoblast invasion. Hum Reprod 2007; 22: 2523-2527. (Pubitemid 47296606)
68. Li Z, Zhang Y, Ying Ma J, Kapoun AM et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007; 50: 686-692. (Pubitemid 47442732)
69. Villa P, Taipale P, Räikkönen K et al. PREDO trial-acetylsalicylic acid in preventing pre-eclampsia in high-risk women. Pregnancy Hypertension 2010; 1: S20.